The vital role of CD19+CD24hiCD38hi regulatory B cells in rheumatoid arthritis: correlations with disease activity and treatment response

Regulatory B cells (Bregs) play a pivotal role in the immune modulation of rheumatoid arthritis (RA). The levels of CD19+CD24hiCD38hi Bregs in peripheral blood and their association with clinical indicators in RA patients have not been extensively studied. The aim of this study was to investigate the alterations in peripheral blood CD19+CD24hiCD38hi Breg levels in RA patients and their association with clinical indicators. Additionally, we explored the variations in Breg levels before and after treatment. Overall, 90 patients with newly diagnosed RA and 32 healthy controls were prospectively enrolled. Symptoms and laboratory findings were collected. Flow cytometry and three-color fluorescence antibody labeling were employed to detect CD19+CD24hiCD38hi Breg levels in peripheral blood mononuclear cells (PBMCs). The proportion of CD19+CD24hiCD38hi Bregs among mature B lymphocytes was analyzed, and correlations with clinical indicators were examined. A follow-up study of 26 RA patients was conducted to compare changes in Breg levels before and after six months of treatment. The levels of CD19+CD24hiCD38hi Bregs in RA patients were 89.63% of those in healthy controls. No significant differences in Breg levels were observed among patients with different disease activities. There was a positive correlation between CD19+CD24hiCD38hi Breg levels and morning stiffness duration (r = 0.227, p = 0.027), and negative correlations with age and anti-CCP antibody titers (r=-0.234, p = 0.022; r=-0.218, p = 0.036). No significant correlations were found between Breg proportions and other clinical indicators. The follow-up study showed a decrease in disease activity scores and a significant increase in CD19+CD24hiCD38hi Breg levels after six months of treatment. These findings suggest a potential association between Breg levels and the pathogenesis and inflammatory activity of RA. CD19+CD24hiCD38hi Bregs may serve as potential biomarkers for evaluating disease activity and treatment efficacy. Further research is warranted to explore the underlying biological mechanisms and clinical significance of Bregs in RA.

Authors

Institutions

Publication Details

Journal
Advances in Rheumatology
Published
2025-09-26
DOI
https://doi.org/10.1186/s42358-025-00474-3
Primary Topic
T-cell and B-cell Immunology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The vital role of CD19+CD24hiCD38hi regulatory B cells in rheumatoid arthritis: correlations with disease activity and treatment response

Xiaoping Hong, Dongzhou Liu, Lijun Chen, Jianjun Xu et al.
Advances in Rheumatology
T-cell and B-cell Immunology
article

The vital role of CD19+CD24hiCD38hi regulatory B cells in rheumatoid arthritis: correlations with disease activity and treatment response

Xiaoping Hong, Dongzhou Liu, Lijun Chen, Jianjun Xu, Heng Li, Bao-Dong Sun
article en

Abstract

Regulatory B cells (Bregs) play a pivotal role in the immune modulation of rheumatoid arthritis (RA). The levels of CD19+CD24hiCD38hi Bregs in peripheral blood and their association with clinical indicators in RA patients have not been extensively studied. The aim of this study was to investigate the alterations in peripheral blood CD19+CD24hiCD38hi Breg levels in RA patients and their association with clinical indicators. Additionally, we explored the variations in Breg levels before and after treatment. Overall, 90 patients with newly diagnosed RA and 32 healthy controls were prospectively enrolled. Symptoms and laboratory findings were collected. Flow cytometry and three-color fluorescence antibody labeling were employed to detect CD19+CD24hiCD38hi Breg levels in peripheral blood mononuclear cells (PBMCs). The proportion of CD19+CD24hiCD38hi Bregs among mature B lymphocytes was analyzed, and correlations with clinical indicators were examined. A follow-up study of 26 RA patients was conducted to compare changes in Breg levels before and after six months of treatment. The levels of CD19+CD24hiCD38hi Bregs in RA patients were 89.63% of those in healthy controls. No significant differences in Breg levels were observed among patients with different disease activities. There was a positive correlation between CD19+CD24hiCD38hi Breg levels and morning stiffness duration (r = 0.227, p = 0.027), and negative correlations with age and anti-CCP antibody titers (r=-0.234, p = 0.022; r=-0.218, p = 0.036). No significant correlations were found between Breg proportions and other clinical indicators. The follow-up study showed a decrease in disease activity scores and a significant increase in CD19+CD24hiCD38hi Breg levels after six months of treatment. These findings suggest a potential association between Breg levels and the pathogenesis and inflammatory activity of RA. CD19+CD24hiCD38hi Bregs may serve as potential biomarkers for evaluating disease activity and treatment efficacy. Further research is warranted to explore the underlying biological mechanisms and clinical significance of Bregs in RA.

Advances in RheumatologyVol. 65(1)
Guangzhou University of Chinese Medicine (CN), Jinan University (CN), Southern University of Science and Technology (CN), Zhuhai People's Hospital (CN), Southern Medical University Shenzhen Hospital (CN), Shenzhen Second People's Hospital (CN)
National Natural Science Foundation of China, Sanming Project of Medicine in Shenzhen, National Postdoctoral Program for Innovative Talents
Openalex Percentile: Top 72%
T-cell and B-cell Immunology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.